Products
Etofenamate is commercially available as gel, emgel, spray, and patch (Rheumalix, Rheumalix forte, Traumalix, Traumalix forte). It has been approved in many countries since 1993.
Structure and properties
Etofenamate (C18H18F3NO4, Mr = 369.4 g/mol) exists as a yellowish, viscous liquid that is practically insoluble in water. Like mefenamic acid and flufenamic acid, it is an anthranilic acid derivative and a fenamate.
Effects
Etofenamate (ATC M02AA06) has analgesic and anti-inflammatory properties. The effects are due to inhibition of cyclooxygenase as well as lipoxygenase, which inhibits the formation of inflammatory mediators. This in contrast to other topical NSAIDs, which inhibit only cyclooxygenase.
Indications
- For the external treatment of pain, inflammation and swelling in sprains, bruises and strains, such as sports injuries.
- As a supportive measure for local treatment of rheumatic complaints of the musculoskeletal system.
Dosage
According to the professional information. The drugs are applied and rubbed several times a day.
Contraindications
- Hypersensitivity, including to flufenamic acid as well as other NSAIDs.
- Infants and young children
- Pregnancy and lactation
- Open, injured, eczematous or diseased skin.
- Application on the mucous membrane
Do not apply over large areas. The application should be reviewed after two weeks. The full precautions can be found in the drug information leaflet.
Interactions
Interactions with other drugs are not known to date.
Adverse effects
Possible adverse effects include local skin reactions such as allergic reactions.
